DRUG - Psychedelic drugs market to break $7B in 2029 led by these 3 meds
2023-09-29 10:00:00 ET
More on psychedelic drugs
- Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies
-
With ecstasy a potential PTSD therapy, psychedelic treatments could take off
-
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
- Psychedelics research amendments advance in House committee
- Cybin in pact to support training in Phase 3 psychedelic trial
For further details see:
Psychedelic drugs market to break $7B in 2029 led by these 3 meds